Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Vietnam Investment Review on MSN
Everest Medicines closes licensing deal with Travere for civorebrutinib
SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and ...
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s growth in IgAN and recent FSGS approval. More on TVTX stock.
Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and their loved ones: the IgA nephropathy patient ...
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, ...
FDA grants accelerated approval to Vera's Trutakna for IgA nephropathy, first dual BAFF/APRIL inhibitor. Competes with ...
EVEREST MED (01952.HK) announced that, in relation to the exclusive licensing and collaboration agreement signed with Travere ...
June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results